This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.
Stocks · News reference
Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target
Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4
Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.
Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development